Clinical trials: Hypertriglyceridemia, active
Lipodystrophy, Diabetes
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
Background: Generalized lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes.
- Conditions
- Lipodystrophy, Diabetes, Hyperlipidemia
- Trial name
- NCT02262832
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hypercholesterolemia, Hypertriglyceridemia
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.
- Conditions
- Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
- Trial name
- NCT06451770
- Testing
- VERVE-201
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 132 people
- Sponsor
- Verve Therapeutics, Inc.
Lipid Metabolism Disorders
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Background: Obesity is known to lead to diseases such as diabetes and high cholesterol (or fats) in the blood (hyperlipidemia). But no one knows why.
- Trial name
- NCT07715890
- Testing
- High fat liquid shake
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertriglyceridemia
A Study of SHR-1918 In Participants With Hypertriglyceridemia
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.
- Trial name
- NCT07349615
- Where
- China
- Volunteers
- 367 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Diabetes, Lipodystrophy
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
Background: Partial lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes.
- Conditions
- Diabetes, Lipodystrophy, Hyperlipidemia
- Trial name
- NCT02262806
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hypertriglyceridemia, Severe Hypertriglyceridemia
A Study to Assess the Safety, Tolerability and Efficacy of ION775
The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG).
- Trial name
- NCT07604974
- Testing
- ION775
- Where
- 17 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertriglyceridemia
Vitamin C Administration and Triglycerides Level in Critical Care Patients
Vitamin C (ascorbic acid) is a water-soluble vitamin with antioxidant properties. Previous studies showed that the administration of vitamin C was associated with decreased triglyceride (TG) levels in ambulatory patients…
- Trial name
- NCT06206759
- Testing
- administration of vitamin C
- Where
- Israel
- Volunteers
- 2,000 people
- Sponsor
- Meir Medical Center
Severe Hypertriglyceridemia
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia.
- Trial name
- SOLARIS-1 (NCT07269210)
- Testing
- Solbinsiran
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Hypertriglyceridemia
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003…
- Trial name
- SHASTA-10 (NCT06822790)
- Testing
- Plozasiran Injection
- Where
- 253 sites in United States, Argentina and 22 more
- Volunteers
- 710 people
- Sponsor
- Arrowhead Pharmaceuticals
Hypertriglyceridemia
A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial in adults with moderate hypertriglyceridemia and diabetic kidney disease.
- Trial name
- NCT07848880
- Testing
- DR10624 Injection
- Where
- 2 sites in China
- Volunteers
- 315 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Hypertriglyceridemia Induced Acute Pancreatitis
Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis
The severity of hypertriglyceridemia induced acute pancreatitis (HTG-AP) is closely related to the serum triglyceride (TG) levels. The higher the TG levels, the greater the risk of developing severe acute pancreatitis (SAP).
- Trial name
- NCT07388420
- Testing
- Evolocumab 140 MG/ML [Repatha], Conventional lipid-lowering therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- General Hospital of Shenyang Military Region
Hypertriglyceridemia, Overweight , Obesity
Standardized Large Yellow Tea Extract for Glucose and Lipid Metabolism in Overweight Adults With Hypertriglyceridemia
This multicenter, prospective, randomized, blinded, parallel-group controlled trial will evaluate the effects of standardized large yellow tea extract on glucose and lipid metabolism in overweight adults with elevated…
- Trial name
- NCT07840846
- Testing
- Standardized Large Yellow Tea Extract
- Volunteers
- 138 people
- Sponsor
- The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to…
- Trial name
- SHASTA-5 (NCT06880770)
- Testing
- Plozasiran
- Where
- 140 sites in United States, Argentina and 25 more
- Volunteers
- 288 people
- Sponsor
- Arrowhead Pharmaceuticals
Cardiovascular, Metabolic Disease
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
- Conditions
- Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder
- Trial name
- NCT07491172
- Testing
- CTX310
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- CRISPR Therapeutics AG
Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis
Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyceridemia at high risk of acute pancreatitis
- Trial name
- NCT07308392
- Testing
- HRS-7249 injection set, SHR-1918 injection set
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabete Mellitus, Obesity & Overweight
Comparing Two Low-Carbohydrate Diets With a Standard Diet in Type 2 Diabetes
Type 2 diabetes is often accompanied by high blood triglycerides and excess weight, and diet plays a central role in managing these conditions together.
- Conditions
- Diabete Mellitus, Obesity & Overweight, Hypertriglyceridaemia
- Trial name
- NCT07801378
- Testing
- High-Protein Low-Carbohydrate Diet, High-Fat Low-Carbohydrate Diet, Standard diet
- Volunteers
- 168 people
- Sponsor
- National Nutrition and Food Technology Institute
Hypertriglyceridemia
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of TG in adults with elevated TG and RC.
- Trial name
- TYDAL-TIMI 78 (NCT07028749)
- Testing
- MAR001
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 316 people
- Sponsor
- Marea Therapeutics
Hypertriglyceridemia
RBD5044 in Chinese Participants With Hypertriglyceridemia
The goal of this clinical trial is to learn if drug RBD5044 works to treat hypertriglyceridemia in adults. It will also learn about the safety of drug RBD5044.
- Trial name
- NCT07587788
- Testing
- RBD5044
- Where
- 7 sites in China
- Volunteers
- 40 people
- Sponsor
- Ribotek Biopharmaceuticals (Shandong) Co., Ltd
Coronary Artery Disease, Hyperlipidaemia
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT
This randomized controlled study will evaluate whether icosapent ethyl (IPE) can improve and stabilize high-risk coronary plaques in patients receiving stable low-density lipoprotein cholesterol (LDL-C)-lowering therapy.
- Conditions
- Coronary Artery Disease, Hyperlipidaemia, Hypertriglyceridaemia, Coronary Atherosclerosis
- Trial name
- IPE-NaF (NCT07762755)
- Testing
- icosapent ethyl (IPE), Standard LDL-C-Lowering Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- China National Center for Cardiovascular Diseases
Intracranial Atherosclerotic Disease (ICAD), Hypertriglyceridaemia
Pemafibrate for Symptomatic ICAS RCT
The goal of this clinical trial is to learn whether pemafibrate can help prevent worsening of intracranial arterial stenosis (ICAS) in patients who have symptomatic ICAS and high triglycerides (TG) levels after ischemic stroke or…
- Conditions
- Intracranial Atherosclerotic Disease (ICAD), Hypertriglyceridaemia, Stroke (CVA) or TIA
- Trial name
- PPAR-ICAS (NCT07562178)
- Testing
- Pemafibrate
- Where
- 37 sites in Japan
- Volunteers
- 270 people
- Sponsor
- Tokyo Women's Medical University